4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3015% below fair value
$10.79−0.50 (-4.43%)
Close on Nov 17, 2026Market cap $778.82MP/E –Yield –
4D Molecular Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
4D Molecular Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$197.12M. For fiscal 2025 it was -$159.55M. The highest annual figure on record is -$50.76M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$159.55M | – |
| FY2024 | Dec 31, 2024 | -$187.84M | – |
| FY2023 | Dec 31, 2023 | -$112.87M | – |
| FY2022 | Dec 31, 2022 | -$110.03M | – |
| FY2021 | Dec 31, 2021 | -$71.33M | – |
| FY2020 | Dec 31, 2020 | -$56.66M | – |
| FY2019 | Dec 31, 2019 | -$50.76M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$77.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$73.62M | – |
| Q4 FY2025 | Dec 31, 2025 | $14.72M | – |
| Q3 FY2025 | Sep 30, 2025 | -$61.19M | – |
| Q2 FY2025 | Jun 30, 2025 | -$59.46M | – |
| Q1 FY2025 | Mar 31, 2025 | -$53.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$56.12M | – |
| Q3 FY2024 | Sep 30, 2024 | -$51.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$42.46M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.14M | – |
| Q4 FY2023 | Dec 31, 2023 | -$36.65M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.97M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.72M | – |
| Q3 FY2022 | Sep 30, 2022 | -$26.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.43M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.39M | – |
| Q4 FY2021 | Dec 31, 2021 | -$24.76M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.66M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.60M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.31M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.42M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.82M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.15M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.28M | – |
See a number that looks wrong?